» Articles » PMID: 38329281

Incremental Value of Amyloid PET in a Tertiary Memory Clinic Setting in China

Abstract

Introduction: The objective of this study is to investigate the incremental value of amyloid positron emission tomography (Aβ-PET) in a tertiary memory clinic setting in China.

Methods: A total of 1073 patients were offered Aβ-PET using F-florbetapir. The neurologists determined a suspected etiology (Alzheimer's disease [AD] or non-AD) with a percentage estimate of their confidence and medication prescription both before and after receiving the Aβ-PET results.

Results: After disclosure of the Aβ-PET results, etiological diagnoses changed in 19.3% of patients, and diagnostic confidence increased from 69.3% to 85.6%. Amyloid PET results led to a change of treatment plan in 36.5% of patients. Compared to the late-onset group, the early-onset group had a more frequent change in diagnoses and a higher increase in diagnostic confidence.

Discussion: Aβ-PET has significant impacts on the changes of diagnoses and management in Chinese population. Early-onset cases are more likely to benefit from Aβ-PET than late-onset cases.

Highlights: Amyloid PET contributes to diagnostic changes and its confidence in Chinese patients. Amyloid PET leads to a change of treatment plans in Chinese patients. Early-onset cases are more likely to benefit from amyloid PET than late-onset cases.

Citing Articles

Locus Coeruleus Degeneration in Essential Tremor With Mild Cognitive Impairment: A Neuromelanin MRI Study.

Fang Y, Zhou C, Zhu B, Liu J, Liu S, Guan X CNS Neurosci Ther. 2025; 31(1):e70214.

PMID: 39777994 PMC: 11707437. DOI: 10.1111/cns.70214.


Incremental value of amyloid PET in a tertiary memory clinic setting in China.

Chen K, Wang M, Wu J, Zuo C, Huang Y, Wang W Alzheimers Dement. 2024; 20(4):2516-2525.

PMID: 38329281 PMC: 11032579. DOI: 10.1002/alz.13728.

References
1.
Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

2.
Zhang Y, Luo H, Wong G, Zhao M, Lv X, Lum T . Prescription Patterns of Antidementia and Psychotropic Drugs in People Living With Dementia: Findings From the Clinical Pathway Study of Alzheimer's Disease in China. J Am Med Dir Assoc. 2021; 23(6):1073-1079.e3. DOI: 10.1016/j.jamda.2021.07.017. View

3.
Kvello-Alme M, Brathen G, White L, Sando S . Time to Diagnosis in Young Onset Alzheimer's Disease: A Population-Based Study from Central Norway. J Alzheimers Dis. 2021; 82(3):965-974. PMC: 8461696. DOI: 10.3233/JAD-210090. View

4.
Gao F, Lv X, Dai L, Wang Q, Wang P, Cheng Z . A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study. Alzheimers Dement. 2022; 19(3):749-760. DOI: 10.1002/alz.12700. View

5.
Contador J, Vargas-Martinez A, Sanchez-Valle R, Trapero-Bertran M, Llado A . Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. Eur Arch Psychiatry Clin Neurosci. 2022; 273(1):243-252. DOI: 10.1007/s00406-022-01439-z. View